Provider profile
Authorized cash-pay vial or pen programs — compounded GLP-1 pricing & profile
Captured pricing, fees, pharmacy disclosure, and evidence status — provider-reported, not checkout-verified.
Authorized cash-pay vial or pen programs is a manufacturer / brand-access channel — a channel for FDA-approved products, profiled here for context but never ranked as a compounded provider. Compounded and approved products are different regulatory classes and are not compared on the same axis.
Captured pricing
Authorized cash-pay vial or pen programs does not publish a single flat compounded price in the captured data. Semaglutide: Current authorized Wegovy cash-pay examples: pill $149–$299/month by dose; pen $199 introductory then $349 standard; HD pen $399. Tirzepatide: Current authorized Zepbound cash-pay examples: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5–15 mg when program conditions are met. Because no stable per-plan figure was captured, Authorized cash-pay vial or pen programs is shown for transparency but is not placed in the ranked pricing tables. Confirm current pricing on the provider's own page before relying on any figure.
Fees, pharmacy, and disclosure
| Category | Manufacturer / brand-access channel |
| Current status | Access category — profile, never ranked as a provider |
| Membership / program fee | Medication; supplies may be separate |
| Pharmacy disclosure | Not verified |
| Material relationship | No known material relationship — publisher attested 2026-07-20; independent verification not performed |
| Evidence status | PROVIDER REPORTED · confidence high |
| Last checked | 2026-07-20 |
| Official source | provider page |
Capture note: This is a category, not one provider. Keep separate product records and avoid double-counting LillyDirect/NovoCare.
How to read this channel
As a manufacturer or brand-access channel, Authorized cash-pay vial or pen programs supplies FDA-approved product, which carries premarket-reviewed manufacturing that compounded products do not. If you have insurance coverage or qualify for a manufacturer cash-pay program, an approved product can be cheaper and better-evidenced than any compounded option — price that first. See the brand-vs-compounded cost guide. This channel is never ranked against compounded providers.
Frequently asked questions
How much does Authorized cash-pay vial or pen programs charge for compounded GLP-1?
Authorized cash-pay vial or pen programs did not publish a single flat compounded price in the captured data — current authorized wegovy cash-pay examples: pill $149–$299/month by dose; pen $199 introductory then $349 standard; hd pen $399. Confirm current pricing directly with the provider, and compute effective monthly cost at your maintenance dose before comparing.
Does Authorized cash-pay vial or pen programs charge a membership fee?
As a brand-access channel, its fee structure differs from compounded telehealth. Captured: Medication; supplies may be separate. A required membership belongs in the effective-cost math, so add it in before comparing Authorized cash-pay vial or pen programs to any flat-priced provider.
Is Authorized cash-pay vial or pen programs's pricing verified?
No. Authorized cash-pay vial or pen programs's evidence status is provider reported (confidence high); figures are provider-reported or independently calculated, not checkout-verified, and its pharmacy disclosure is "not verified". Treat every figure as a starting point to confirm, not a guarantee.